中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
14期
5-6
,共2页
重组人促红细胞生成素-β%重组人促红细胞生成素-α%肾性贫血
重組人促紅細胞生成素-β%重組人促紅細胞生成素-α%腎性貧血
중조인촉홍세포생성소-β%중조인촉홍세포생성소-α%신성빈혈
rHuEPO- β%rHuEPO- α%Renal anemia
目的:比较重组人促红细胞生成素-β(rHuEPO-β)和重组人促红细胞生成素-α(rHuEPO-α)治疗肾性贫血的疗效和不良反应。方法选取2012年2月至2013年5月在枣庄市市中区人民医院维持性血液透析且血红蛋白(Hb)<90 g/ L 的患者49例为研究对象,随机分为两组,分别应用 rHuEPO-β(实验组)和 rHuEPO-α(对照组)皮下注射治疗,观察比较两组治疗前后 Hb、红细胞压积变化、达到 Hb 目标值平均时间及促红细胞生成素(EPO)平均使用剂量,并观察不良反应的发生情况。结果两组治疗4周后 Hb 较治疗前明显升高(P <0.05);治疗4、8、12周后,实验组 Hb 均较对照组高(P <0.05);治疗16周后,两组 Hb 水平比较差异无统计学意义(P >0.05)。实验组患者 Hb 达到目标值平均使用天数及平均使用 EPO 剂量较对照组少(P <0.05)。实验组较对照组不良反应发生率低。结论皮下注射 rHuEPO-β和 rHuEPO-α治疗肾性贫血均有效,但 rHuEPO-β治疗肾性贫血较rHuEPO-α起效快,用量少,依从性好,不良反应少。
目的:比較重組人促紅細胞生成素-β(rHuEPO-β)和重組人促紅細胞生成素-α(rHuEPO-α)治療腎性貧血的療效和不良反應。方法選取2012年2月至2013年5月在棘莊市市中區人民醫院維持性血液透析且血紅蛋白(Hb)<90 g/ L 的患者49例為研究對象,隨機分為兩組,分彆應用 rHuEPO-β(實驗組)和 rHuEPO-α(對照組)皮下註射治療,觀察比較兩組治療前後 Hb、紅細胞壓積變化、達到 Hb 目標值平均時間及促紅細胞生成素(EPO)平均使用劑量,併觀察不良反應的髮生情況。結果兩組治療4週後 Hb 較治療前明顯升高(P <0.05);治療4、8、12週後,實驗組 Hb 均較對照組高(P <0.05);治療16週後,兩組 Hb 水平比較差異無統計學意義(P >0.05)。實驗組患者 Hb 達到目標值平均使用天數及平均使用 EPO 劑量較對照組少(P <0.05)。實驗組較對照組不良反應髮生率低。結論皮下註射 rHuEPO-β和 rHuEPO-α治療腎性貧血均有效,但 rHuEPO-β治療腎性貧血較rHuEPO-α起效快,用量少,依從性好,不良反應少。
목적:비교중조인촉홍세포생성소-β(rHuEPO-β)화중조인촉홍세포생성소-α(rHuEPO-α)치료신성빈혈적료효화불량반응。방법선취2012년2월지2013년5월재조장시시중구인민의원유지성혈액투석차혈홍단백(Hb)<90 g/ L 적환자49례위연구대상,수궤분위량조,분별응용 rHuEPO-β(실험조)화 rHuEPO-α(대조조)피하주사치료,관찰비교량조치료전후 Hb、홍세포압적변화、체도 Hb 목표치평균시간급촉홍세포생성소(EPO)평균사용제량,병관찰불량반응적발생정황。결과량조치료4주후 Hb 교치료전명현승고(P <0.05);치료4、8、12주후,실험조 Hb 균교대조조고(P <0.05);치료16주후,량조 Hb 수평비교차이무통계학의의(P >0.05)。실험조환자 Hb 체도목표치평균사용천수급평균사용 EPO 제량교대조조소(P <0.05)。실험조교대조조불량반응발생솔저。결론피하주사 rHuEPO-β화 rHuEPO-α치료신성빈혈균유효,단 rHuEPO-β치료신성빈혈교rHuEPO-α기효쾌,용량소,의종성호,불량반응소。
Objective To compare the curative effect and adverse reaction of recombinant hu-man erythropoietin beta(rHuEPO-β)and recombinant human erythropoietin alpha( rHuEPO-α)in the treatment of renal anemia. Methods Forty-nine patients unterwent maintenance hemodialysis and hemo-globin(Hb) < 90 g / L from February 2012 to May 2013 in people’s hospital of Shizhong district of Zaozhuang were chose as the object of study,and were divided into two groups randomly. Experimental group was given rHuEPO-β with subcutaneous injection and control group was given rHuEPO-α with sub-cutaneous injection respectively. The hemoglobin,hematocrit changes,the average time to achieve Hb targets value,the average dose of erythropoietin( EPO)using,and adverse reactions between the two groups before and after treatment was compared. Results Compared with before treatment,the levels of Hb in both groups increased significantly at 4 weeks after treatment(P < 0. 05);the levels of Hb in ex-perimental group were higher than that in control group at 4,8,12 weeks after treatment(P < 0. 05);af-ter 16 weeks of treatment,there was no significant difference in Hb levels between the two groups(P >0. 05). The average time to achieve Hb targets value and the average dose of erythropoietin(EPO)using in the experimental group were lower than those in the control group(P < 0. 05). The experimental group had less adverse reaction than that in the control group. Conclusions Subcutaneous injection of rHuE-PO-β and rHuEPO-α in treatment of renal anemia are effective,but rHuEPO-β has more rapid onset, less dosage,better compliance and less adverse reaction than rHuEPO-α in treatment of renal anemia.